Results
Aurobindo Pharma Q4 FY26 Revenue ₹8,853 Crores, EBITDA ₹1,801 Crores
Aurobindo Pharma reported its highest-ever annual revenue of ₹33,653 crores and EBITDA of ₹6,856 crores for FY26, with a margin of 20.4%.
Q4 FY26 revenue was ₹8,853 crores with EBITDA of ₹1,801 crores
